A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Neovii Biotech
ClinicalTrials.gov Identifier:
NCT01320020
First received: March 21, 2011
Last updated: July 1, 2013
Last verified: May 2013

March 21, 2011
July 1, 2013
February 2011
March 2013   (final data collection date for primary outcome measure)
Maximal Tolerated Dose [ Time Frame: The dose escalation schedule is based on a Modified Fibonacci Schedule ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01320020 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients
A Phase I, Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

The study is designed as an open-label dose-escalation study to investigate the safety and tolerability of catumaxomab qwk in patients with epithelial cancer. The treatment period for dose escalation (dose limiting toxicity (DLT) period) consists of 4 weeks, comprising 4 single i.v. administrations of catumaxomab followed by 1 week for safety observations after each administration. All patients will be offered continuation of catumaxomab treatment at the same dose until disease progression or death, whichever occurs first.

Epithelial cancer patients who are progressing on or after standard therapy or for whom no standard therapy exists. Catumaxomab (trifunctional anti-EpCAM x anti-CD3 antibody)Catumaxomab will be administered i.v. once weekly (qwk) with each infusion lasting for 6 hours. The starting dose for catumaxomab will be 2 µg. The dose escalation schedule is based on a Modified Fibonacci Schedule with the following dose cohorts: 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose. Subsequent dose levels will correspond to dosing increments of about 30%, e.g. 25, 33, 43, 56 µg. After completion of the DLT period, all patients will be offered continuation of catumaxomab treatment at the same dose until disease progression or death, whichever occurs first. The maximum length of treatment, however, will be restricted to an additional 12 weeks after the DLT period - resulting in a maximum treatment duration of 16 weeks total.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Epithelial Cancer Patients
Drug: catumaxomab
Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
Experimental: catumaxomab
Intervention: Drug: catumaxomab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
16
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with epithelial cancer known to have EpCAM overexpression in at least 80% of patients, progressing on or after standard therapy or for whom no standard therapy exists.
  2. At least one assessable lesion according to RECIST in at least one dimension on computed tomography (CT).
  3. Life expectancy ≥ 3 months.
  4. Age ≥ 18 years.
  5. ECOG Performance Status ≤ 1
  6. Females of childbearing potential must have a negative serum pregnancy test within 48 hours prior to first infusion of catumaxomab and must use an effective contraception (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, injections with prolonged release) during the study and at least 13 days after participating in the study.
  7. Patients capable to understand the purposes and risks of the study, who are willing and able to participate in the study and from whom written and dated informed consent to participate in the study has been obtained.

Exclusion Criteria:

  1. Patients with known clinically symptomatic brain metastases.
  2. Concomitant cancer chemo- or radiotherapy (except for local radiation therapy for bone marrow metastasis)
  3. Treatment with any investigational product within 4 weeks prior to first administration of catumaxomab
  4. In cases of previous exposure to cancer-, chemo-, immune- or radiotherapy (except for local radiation therapy for bone marrow metastasis) patients must be excluded if not sufficiently recovered from previous treatment (toxicity present) based on adequate laboratory values and general status according to other in/exclusion criteria (i.e. this might be less than 1 or 2 weeks after a weekly or bi-weekly scheduled previous therapy regimen).
  5. Exposure to nitrosoureas or mitomycin C within 6 weeks prior to the first infusion of catumaxomab.
  6. Abnormal organ or bone marrow function as defined below (any single parameter to fulfill condition):

    6.1. ANC < 1.5 (1.5x109/L, 1500/mm3) 6.2. Hemoglobin < 9.0 g/dL 6.3. Platelet count < 75 (75x109/L, 75,000/mm³) 6.4. AST(SGOT)/ALT(SGPT) > 3 x upper limit of normal (ULN); 6.5. Alkaline phosphatase > 2.5 x ULN 6.6. Serum (total) bilirubin > 1.5 x ULN; 6.7. Serum creatinine > 1.5 x ULN; 6.8. Serum creatinine > 1.5 x ULN (exception: pts on anticoagulant therapy)

  7. Use of immune-suppressive agents for the past 4 weeks prior to first administration of catumaxomab. For regular use of systemic corticosteroids, patients should only be included after stepwise discontinuation to be free of steroids for a minimum of 5 days prior to first administration of catumaxomab.
  8. Any known active or chronic infection.
  9. Known infection with human immunodeficiency virus (HIV positive) and/or hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive).
  10. Any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the study as judged by the investigator.
  11. Known hypersensitivity to catumaxomab and its analogues in general, or to any other component of the study drug formulation.
  12. Patients with congestive heart failure NYHA Class III and IV. Cardiac arrhythmias (except atrioventricular block type I and II, atrial fibrillation/flutter, bundle brunch block) or other signs and symptoms of relevant cardiovascular disease.
  13. Pregnant women, nursing mothers, lactating women, and women of child-bearing potential who are unwilling to use effective contraception (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, injections with prolonged release). Effective contraception must be used for the duration of the study and for at least 13 days after participating in the study. Effective contraception must be used by men and women for the duration of the study and for at least 13 days after participating in the study.
  14. Unwilling or unable to follow protocol requirements.
  15. Patients with a history of liver cirrhosis
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain,   Denmark,   Austria
 
NCT01320020
IV-CAT-ST-01
Yes
Neovii Biotech
Neovii Biotech
Not Provided
Study Chair: Josep Tabernero, MD Vall d'Hebron University Hospital, Barcelona, Spain
Principal Investigator: Christian Dittrich, Prim.Univ.-Prof. Zentrum für Onkologie und Hämatologie, Kaiser Franz Josef-Spital, Wien, Austria
Principal Investigator: Morten Sorenesen, MD, Ph.D. The Finsen Center, Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Neovii Biotech
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP